In recent years, depression studies have focused on morphological changes associated with depression. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor that plays an important role in the morphological changes associated with depression and the mechanisms of antidepressants. On the other hand, hyperfunction of the hypothalamic-pituitary-adrenal axis has been link to pathophysiology of depression. In our previous studies, ACTHtreated rats served as a valuable animal model of tricyclic antidepressant-resistant depressive conditions. However, few neuroanatomic studies have been done. In the present study, we investigated mechanisms underling ACTH-treated rat serving an imipramine treatment-resistant depression model using c-Fos as a marker. The c-Fos immunohistochemical study indicated that the medial prefrontal cortex is an action site of imipramine in ACTH-treated rats. Electroconvulsive therapy is considered an eŠective treatment for treatment-resistant depression. However, the mechanisms causing treatment-resistant depressive conditions are unknown. We investigated the eŠect of repeated electrical convulsive shock (ECS)-treatment using the forced swim test, a screening method for antidepressant-like activity, and hippocampal BDNF protein levels in ACTH-treated rats. Findings showed that repeated ECS treatment decreased the immobility time during forced swim test. Furthermore, the ECS treatment also markedly increased the hippocampal BDNF levels in the rat tricyclic antidepressant-resistant depression model. In addition, the repeated ECS treatment showed long-lasting eŠects on forced swim test and increased of hippocampal BDNF levels in normal rats. Theseˆndings suggest that BDNF plays a key role in the antidepressant-like eŠect of ECS and that increased BDNF may be involved in promoting the longlasting eŠect.
(Received January 5, 2007) In recent years, depression studies have focused on morphological changes associated with depression. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor that plays an important role in the morphological changes associated with depression and the mechanisms of antidepressants. On the other hand, hyperfunction of the hypothalamic-pituitary-adrenal axis has been link to pathophysiology of depression. In our previous studies, ACTHtreated rats served as a valuable animal model of tricyclic antidepressant-resistant depressive conditions. However, few neuroanatomic studies have been done. In the present study, we investigated mechanisms underling ACTH-treated rat serving an imipramine treatment-resistant depression model using c-Fos as a marker. The c-Fos immunohistochemical study indicated that the medial prefrontal cortex is an action site of imipramine in ACTH-treated rats. Electroconvulsive therapy is considered an eŠective treatment for treatment-resistant depression. However, the mechanisms causing treatment-resistant depressive conditions are unknown. We investigated the eŠect of repeated electrical convulsive shock (ECS)-treatment using the forced swim test, a screening method for antidepressant-like activity, and hippocampal BDNF protein levels in ACTH-treated rats. Findings showed that repeated ECS treatment decreased the immobility time during forced swim test. Furthermore, the ECS treatment also markedly increased the hippocampal BDNF levels in the rat tricyclic antidepressant-resistant depression model. In addition, the repeated ECS treatment showed long-lasting eŠects on forced swim test and increased of hippocampal BDNF levels in normal rats. Theseˆndings suggest that BDNF plays a key role in the antidepressant-like eŠect of ECS and that increased BDNF may be involved in promoting the longlasting eŠect. ECS was administered for 6 or 14 days, and imipramine (10 mg/kg, i.p.) was administered for 14 days. ECS or imipramine was administered 30 min after the administration of ACTH or saline. Open-ˆeld test was performed 24 h after last ECS treatment.  p＜0.05,    p＜0.001. Two-way ANOVA followed by Student's ttest. Mean±S.E., n＝6-9. Rats were treated with ACTH (100 mg/rat s.c.) once daily for 14 days. ECS treatment was performed 30 min after ACTH or saline treatment. Measurement of the (±)-DOI-induced wet-dog shake response was performed 24 h after theˆnal treatment with ACTH.   p＜0.01,    p＜0.001, Two-way ANOVA followed by Student's t-test. Mean±S.E., n＝8-9. ECS was administered for 6 or 14 days, and imipramine (10 mg/kg, i.p.) was administered for 14 days. ECS or imipramine was administered 30 min after the administration of ACTH or saline. BDNF sampling was performed 24 h after last ECS or imipramine treatment.  p＜0.05,   p＜0.01 Two-way ANOVA followed by Student's t-test. Mean±S.E., n＝6-8. 
